貨號:A522450
同義名:
2-(1,8-Naphthyridin-2-yl)phenol
2-NP是一種選擇性的 STAT1 轉錄增強劑,能夠增強 IFN-γ 抑制人乳腺癌和纖維肉瘤細胞增殖的能力,通過調節免疫反應發揮抗癌作用,適用于癌癥免疫治療的研究。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 規格 | 價格 | 會員價 | 庫存 | 數量 | ||||
|---|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} | 咨詢 | 咨詢 |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 現貨 1周 咨詢 | - + |
快速發貨 順豐冷鏈運輸,1-2 天到達
品質保證
技術支持
免費溶解

| 產品名稱 | JAK1 ↓ ↑ | JAK2 ↓ ↑ | JAK3 ↓ ↑ | Tyk2 ↓ ↑ | 其他靶點 | 純度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decernotinib |
+++
JAK1, IC50: 11 nM JAK1, Ki: 11 nM |
+++
JAK2, Ki: 13 nM |
++++
JAK3, Ki: 2.5 nM |
+++
TYK2, Ki: 13 nM |
99%+ | ||||||||||||||
| ZM39923 HCl |
+
JAK1, pIC50: 4.4 |
+
JAK3, pIC50: 7.1 |
EGFR | 97% | |||||||||||||||
| Cerdulatinib |
+++
JAK1, IC50: 12 nM |
+++
JAK2, IC50: 6 nM |
+++
JAK3, IC50: 8 nM |
++++
TYK2, IC50: 0.5 nM |
99%+ | ||||||||||||||
| Momelotinib |
+++
JAK1, IC50: 11 nM |
++
JAK2, IC50: 18 nM |
+
JAK3, IC50: 155 nM |
99%+ | |||||||||||||||
| XL019 |
+
JAK1, IC50: 134.3 nM |
++++
JAK2, IC50: 2.2 nM |
+
JAK3, IC50: 214.2 nM |
FLT3 | 99%+ | ||||||||||||||
| Ruxolitinib |
+++
JAK1, IC50: 3.3 nM |
++++
JAK2, IC50: 2.8 nM |
98% | ||||||||||||||||
| Tofacitinib |
+
JAK1, IC50: 112 nM |
++
JAK2, IC50: 20 nM |
++++
JAK3, IC50: 1 nM |
98% | |||||||||||||||
| Ruxolitinib (S enantiomer) |
+++
JAK1, IC50: 3.3 nM |
++++
JAK2, IC50: 2.8 nM |
++
TYK2, IC50: 19 nM |
98% | |||||||||||||||
| Filgotinib |
+++
JAK1, IC50: 10 nM |
++
JAK2, IC50: 28 nM |
+
JAK3, IC50: 810 nM |
+
TYK2, IC50: 116 nM |
99% | ||||||||||||||
| Baricitinib |
+++
JAK1, IC50: 5.9 nM |
+++
JAK2, IC50: 5.7 nM |
++
TYK2, IC50: 53 nM |
99% | |||||||||||||||
| Gandotinib |
++
JAK1, IC50: 19.8 nM |
++++
JAK2, IC50: 0.288 nM JAK2 (V617F), Ki: 0.245 nM |
++
JAK3, IC50: 48.0 nM |
++
TYK2, IC50: 44 nM |
FLT3 | 99%+ | |||||||||||||
| Oclacitinib maleate |
+++
JAK1, IC50: 10nM |
++
JAK2, IC50: 18nM |
+
JAK3, IC50: 99nM |
+
TYK2, IC50: 84nM |
98+% | ||||||||||||||
| NVP-BSK805 2HCl |
++
JAK1, IC50: 31.63 nM |
++++
JAK2, IC50: ~0.5 nM |
++
JAK3, IC50: 18.68 nM |
+++
TYK2, IC50: 10.76 nM |
98% | ||||||||||||||
| Peficitinib | ? | 98% | |||||||||||||||||
| Go6976 | ? | FLT3 | 99%+ | ||||||||||||||||
| AZD-1480 |
++++
JAK2, IC50: 0.26 nM |
99%+ | |||||||||||||||||
| Fedratinib |
+++
JAK2, IC50: 3 nM JAK2 (V617F), IC50: 3 nM |
RET,FLT3 | 99%+ | ||||||||||||||||
| WP1066 |
+
JAK2, IC50: 2.3 μM |
98% | |||||||||||||||||
| Curcumol | ? | 98% | |||||||||||||||||
| AZ960 |
++++
JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM |
97% | |||||||||||||||||
| GLPG0634 analog | ? | 99%+ | |||||||||||||||||
| CEP-33779 |
++++
JAK2, IC50: 1.8 nM |
99%+ | |||||||||||||||||
| FLLL32 |
+
JAK2, IC50: <5 μM |
99%+ | |||||||||||||||||
| WHI-P154 |
+
JAK3, IC50: 1.8 μM |
Src,VEGFR,EGFR | 98% | ||||||||||||||||
| BMS-911543 |
++++
JAK2, IC50: 1.1 nM |
+
JAK3, IC50: 75 nM |
++
TYK2, IC50: 66 nM |
95% | |||||||||||||||
| TG101209 |
+++
JAK2, IC50: 6 nM |
+
JAK3, IC50: 169 nM |
RET,FLT3 | 99%+ | |||||||||||||||
| AT9283 |
++++
JAK2, IC50: 1.2 nM |
++++
JAK3, IC50: 1.1 nM |
99%+ | ||||||||||||||||
| Pacritinib |
++
JAK2, IC50: 23 nM JAK2 (V617F), IC50: 19 nM |
+
JAK3, IC50: 520 nM |
++
TYK2, IC50: 50 nM |
FLT3 | 97% | ||||||||||||||
| Tofacitinib citrate |
++
JAK2, IC50: 20 nM |
++++
JAK3, IC50: 1 nM |
99% | ||||||||||||||||
| FM-381 |
++++
JAK3, IC50: 127 pM |
98% | |||||||||||||||||
| 1. 鼠標懸停在“+”上可以顯示相關IC50的具體數值。"+"越多,抑制作用越強。2. "?"表示該化合物對相應的亞型有抑制作用,但抑制強度暫時沒有相關數據。 | |||||||||||||||||||
| 產品名稱 | STAT1 ↓ ↑ | STAT3 ↓ ↑ | STAT5 ↓ ↑ | 其他靶點 | 純度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nifuroxazide | ? | 98% | |||||||||||||||||
| Fludarabine | ? | 98% | |||||||||||||||||
| Artesunate | ? | 98% | |||||||||||||||||
| BP-1-102 |
+++
STAT3, Kd: 504 nM |
99%+ | |||||||||||||||||
| Niclosamide |
++
STAT3, IC50: 0.7 μM |
98% | |||||||||||||||||
| Napabucasin | ? | 98% | |||||||||||||||||
| Cryptotanshinone |
++
STAT3, IC50: 4.6 μM |
98% | |||||||||||||||||
| Stattic |
+
STAT3, IC50: 5.1 μM |
98% | |||||||||||||||||
| NSC 74859 |
+
STAT3, IC50: 86 μM |
99%+ | |||||||||||||||||
| Ochromycinone | ? | 98% | |||||||||||||||||
| HO-3867 | ? | 97% | |||||||||||||||||
| C188-9 |
++++
STAT3, Kd: 4.7 nM |
99%+ | |||||||||||||||||
| HJC0152 | ? | 99% | |||||||||||||||||
| SH5-07 | ? | 95% | |||||||||||||||||
| SH-4-54 |
++++
STAT3, Kd: 300 nM |
+++
STAT5, Kd: 464 nM |
99%+ | ||||||||||||||||
| 1. 鼠標懸停在“+”上可以顯示相關IC50的具體數值。"+"越多,抑制作用越強。2. "?"表示該化合物對相應的亞型有抑制作用,但抑制強度暫時沒有相關數據。 | |||||||||||||||||||
| Administration | Dosage | Frequency | Description | References | ||
| Sprague-Dawley rats | Subarachnoid hemorrhage (SAH) model | Intracerebroventricular injection | 15 μg/kg | Single administration 48 hours before SAH | 2-NP reversed the effects of PEDF-34 on p-STAT1, CFB, and C3 expression, promoted A1 astrocyte polarization, and increased inflammatory cytokine secretion. | J Neuroinflammation. 2024 Jul 21;21(1):178 |
| 計算器 | ||||
| 存儲液制備 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
4.50mL 0.90mL 0.45mL |
22.50mL 4.50mL 2.25mL |
45.00mL 9.00mL 4.50mL |
|
| CAS號 | 65182-56-1 |
| 分子式 | C14H10N2O |
| 分子量 | 222.24 |
| SMILES Code | OC1=CC=CC=C1C2=NC3=NC=CC=C3C=C2 |
| MDL No. | MFCD00203050 |
| 別名 | 2-(1,8-Naphthyridin-2-yl)phenol |
| 英文名稱 | 2-(1,8-Naphthyridin-2-yl)phenol |
| 運輸 | 藍冰 |
| 存儲條件 |
In solvent -20°C: 3-6個月 -80°C: 12個月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO 中的溶解度 : 50 mg/mL (224.97 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響,請使用新開封的 DMSO) 以下溶解方案都請先按照體外實驗的方式配制澄清的儲備液,再依次添加助溶劑: ——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議現用現配,當天使用; 以下溶劑前顯示的百分比是指該溶劑在終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶
|
滬公網安備 31011002007707號
滬ICP備2025150922號-1
?;方洜I許可證:滬(楊)應急管危經許[2025]204822(QY)